INTRASTROMAL INJECTION VERSUS TOPICAL DROPS OF VORICONAZOLE FOR RESISTANT FUNGAL CORNEAL ULCER

A 54-year-old Caucasian woman presented with corneal ulcer of the right eye of 4 weeks duration after scratching her cornea while removing her contact lens and artificial eye lashes. Her visual acuity was 20/32 (left eye) and finger counting (right eye). She had a 3x3 mm epithelial defect with underlying corneal oedema and hypopyon. Right eye cultures grew Paecilomyces species. Topical and systemic antifungal agents were initiated. Due to the sight-threatening disease, the patient underwent surgical intervention with intrastromal injection of amphotericin B and a large conjunctival flap covering 75% of the right eye corneal ulcer. After 3 months of therapy, she had near-complete resolution of the corneal ulcer. Unfortunately, recurrence of the corneal ulcer occurred within 3 weeks of cessation of therapy, prompting reinitiation of ophthalmic and systemic antifungal agents. The patient was advised to continue therapy for 6 months with regular follow-up.

Download Full-text

A Case of Conjunctival Autotransplantation Using Conjunctival Flap of Pterygium in Treating Corneal Ulcer Perforation

Journal of the Korean Ophthalmological Society ◽

10.3341/jkos.2008.49.12.2006 ◽

2008 ◽

Vol 49 (12) ◽

pp. 2006 ◽

Cited By ~ 1

Author(s):

Sang Moon Jeoung ◽

Jae Seok Im ◽

Dong Park

Keyword(s):

Corneal Ulcer ◽

Ulcer Perforation ◽

Conjunctival Flap

Download Full-text

Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases

Vision ◽

10.3390/vision5030034 ◽

2021 ◽

Vol 5 (3) ◽

pp. 34

Author(s):

Ronald M. Sánchez-Ávila ◽

Edmar Uribe-Badillo ◽

Carlos Fernández-Vega González ◽

Francisco Muruzabal ◽

Borja de la Sen-Corcuera ◽

...

Keyword(s):

Growth Factors ◽

Corneal Ulcer ◽

Disease Index ◽

Eye Drops ◽

Analog Scale ◽

Ocular Surface Disease Index ◽

Corneal Ulcers ◽

Corrected Visual Acuity ◽

The Mean

This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers. RGTA treatment was applied (one drop every two days); however, if ulcer closure was not achieved, PRGF eye drops treatment was added (four times/day). The time taken to reach the ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder (n = 27, 34.2%), mainly for herpes virus (n = 15, 19.0%). The time of PRGF eye drops treatment associated with the RGTA matrix was 4.2 ± 2.2 (1.5–9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p < 0.001), and IOP remained unchanged (p = 0.665). RGTA and PRGF in noninfectious ulcers were effective and could be a therapeutic alternative for this type of corneal disease.

Download Full-text